Treatment of Metastatic Prostate Cancer
common.study.values.description
“A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer”
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Niraparib
Participants will receive niraparib 200 mg (2 capsules of 100 mg each) capsules once daily.
Drug - Abiraterone Acetate
Participants will receive abiraterone acetate 1000 mg (4 tablets of 250 mg each) tablets once daily.
Drug - Prednisone
Participants will receive prednisone 10 mg (2 tablets of 5 mg each) tablets daily.
Drug - Placebo
Participants will receive matching placebo capsules once daily.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
common.study.values.clinical-trial-id
NCT03748641
participant.views.study.view.id
bkR6Xa
